A Phase I Open-Label Safety Study of Escalating Doses of Taxol [paclitaxel] in Combination With Escalating Doses of GEM231 in Patients With Refractory Solid Tumors

Trial Profile

A Phase I Open-Label Safety Study of Escalating Doses of Taxol [paclitaxel] in Combination With Escalating Doses of GEM231 in Patients With Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs GEM 231 (Primary) ; Paclitaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Jul 2008 Status change
    • 27 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top